May 21, 2019
Debiopharm enrolls patient to test treatment in solid tumors
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
May 21, 2019
Design contract for UK’s first Vaccines Manufacturing Innovation Centre won by WHP
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
May 20, 2019
Merck Keytruda in triple-negative breast cancer (TNBC) study misses its pre-specified primary endpoint of superioroverall survival (OS) compared to chemotherapy
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
May 20, 2019
Verona Pharma finds more symptoms benefits from ensifentrine in COPD patients
Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.
May 20, 2019
Global pulmonary embolism therapeutics market to post 9% CAGR over next five years
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
May 20, 2019
Global $18.3 Bn Atopic Dermatitis Drug Forecast and Market Analysis to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027” report has been added to ResearchAndMarkets.com’s offering. The…
May 16, 2019
Testing Pradaxa vs acetylsalicylic acid for preventing recurrent stroke misses its goal: Boehringer Ingelheim
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.
May 16, 2019
Entrectinib shrank tumours ORR in all children and adolescents: Roche study
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.
May 16, 2019
Pharming Group net profit up for Q1 2019
Revenues increased approximately 19.5% to €35.2 million, compared with €29.5 million during the same period last year.
May 16, 2019
4D pharma’s Chron’s treating Thetanix meets objective
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.